The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
作者信息
Lennard M S, Jackson P R, Freestone S, Ramsay L E, Tucker G T, Woods H F
出版信息
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):106S-107S. doi: 10.1111/j.1365-2125.1984.tb02441.x.
Abstract
摘要
相似文献
1
The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.单次给药后普萘洛尔的口服清除率及β-肾上腺素受体拮抗活性与异喹胍氧化表型无关。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):106S-107S. doi: 10.1111/j.1365-2125.1984.tb02441.x.
2
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
3
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
4
Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.异喹胍多态性与美托洛尔、噻吗洛尔、普萘洛尔和阿替洛尔的代谢及作用
Xenobiotica. 1986 May;16(5):435-47. doi: 10.3109/00498258609050250.
5
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
6
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
7
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.人体内去甲替林和安替比林清除率与异喹胍羟化作用的关系。
Life Sci. 1980 Nov 3;27(18):1673-7. doi: 10.1016/0024-3205(80)90642-6.
8
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.人体肝脏氧化的立体选择性和区域选择性——去甲异喹胍/鹰爪豆碱表型对丁呋洛尔羟基化作用的影响
Eur J Clin Pharmacol. 1986;31(3):313-8. doi: 10.1007/BF00981130.
9
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.β受体阻断药物的高血浆浓度与异喹胍羟化不足。
Lancet. 1982 Feb 6;1(8267):333. doi: 10.1016/s0140-6736(82)91583-5.
10
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
引用本文的文献
1
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.人类细胞色素P450 2D6的多态性及其临床意义：第一部分。
Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000.
2
Polymorphic metabolism of beta-adrenoceptor antagonists.β-肾上腺素受体拮抗剂的多态性代谢
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):11S-19S. doi: 10.1111/j.1365-2125.1984.tb02423.x.
本文引用的文献
1
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
2
An automated HPLC method for the assay of propranolol and its basic metabolites in plasma and urine.一种用于测定血浆和尿液中普萘洛尔及其碱性代谢物的自动高效液相色谱法。
J Chromatogr Sci. 1982 Mar;20(3):126-31. doi: 10.1093/chromsci/20.3.126.
Zotero 插件